Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Burkitt Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia 3Down Syndrome 3Neoplasms 1Lymphoma, T-Cell 1Leukemia, Promyelocytic, Acute 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 12Vincristine 9Etoposide 8venetoclax 6Methotrexate 6Doxorubicin 6Dexamethasone 6Cytarabine 6Prednisone 5Calcium Dobesilate 5prednylidene 4pegaspargase 4merphos 4dexamethasone acetate 4dexamethasone 21-phosphate 4deltacortene 4calaspargase pegol 4auricularum 4Specimen Handling 4Granulocyte Colony-Stimulating Factor 4fludarabine phosphate 3daratumumab 3Thioguanine 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Mercaptopurine 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hydrocortisone 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Mercaptopurine × 90 days × Clear all
NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
847 enrolled 19 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03007147 2026-05-04

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 3 Active not recruiting
475 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06390319 2026-05-01

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

St. Jude Children's Research Hospital

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡